• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.05
  • VXN 17.55
  • VXO 14.25
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

Company Profile

NovaBay Pharmaceuticals Inc., a clinical stage specialty pharmaceutical company, engages in the discovery and development of product candidates for the treatment or prevention of a range of infections in hospital and non-hospital environments. Its Aganocide compounds are synthetic forms of N-chlorinated antimicrobial molecules, which are anti-infective molecules produced by white blood cells when defending the body against invading pathogens. These compounds could form a platform to create various products to address the needs in the treatment and prevention of bacterial, viral, and fungal infections. The company?s lead product candidate, NVC-422, is used for the treatment of eye, ear, and sinus infections, and for use in contact lens solutions, as well as to destroy bacteria in the bladder, and bacteria that have formed biofilm within the catheter. It also develops NVC-101, a solution of hypochlorous acid used as a wound cleanser and debriding agent. NovaBay Pharmaceuticals has a licensing and research collaboration agreement with Alcon Manufacturing Ltd. for use of its Aganocide compounds in the eye, ear, and sinus infections, and for contact lens care, as well as an agreement with Galderma S.A. to develop and commercialize its Aganocide compounds in acne, impetigo, and other dermatological indications. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals was incorporated in 2000 and is based in Emeryville, California.

NBY (NovaBay Pharmaceuticals Inc)
Last Trade 0.6751 Date 9/21/2019
Change % -14.17 % Price Change -0.12
Open 0.71 52 Week High 4.04
High 0.775 52 Week Low 0.229
Low 0.641 Type stock
Volume 2027173 Average Volume 1108474
Prev Close 0.7865 Stock Exchange A
Bid 0.6751 Ask 0.6784
Bid Size 19 Ask Size 2
1st Yr Estimated EPS Growth -0.6137 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 0.0662 Book Value Yield 0.0842
Buy Back Yield CAPE Ratio
Cash Return -0.4154 Cash Flow per Share -0.4922
Cash Flow Yield -0.6258 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.7374 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA -4.8538
EV / Forward Revenue 1.6564 EV / Pre Tax Income
EV / Revenue 2.0774 EV / Total Asset 2.1146
Expected Dividend Growth Rate Free Cash Flow per Share -0.4955
Free Caash Flow Ratio Free Cash Flow Yield -0.6301
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.2797 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 11.876126 PB Ratio 10 Year Growth 0.080862
PB Ratio 3 Year Growth 13.070036 Cash Ratio 3 Year Average 779.0094
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 40.276666 PE Ratio 10 Year Growth
PE Ratio 10 Year High 71.633333 PE Ratio 10 Year Low 16.25
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 1.46653
Price to Cash Ratio 5.403832 Price / EBITDA
Price to Sales Ratio 1.369467 Price to Sales Ratio 10 Year Growth -0.108227
Price to Sales Ratio 3 Year Avg 2.461161 Price to Sales Ratio 5 Year Avg
Sale per Share 0.5743 Sales Yield 0.7302
Sustainable Growth Rate -2.0939 Tangible Book Value per Share 0.0662
Tangible Book Value per Share 3 year Avg 0.3046 Tangible Book Value per Share 5 year Avg 0.7466
Total Asset per Share 0.3916 Total Yield
Working Capital per Share 0.1644 Working Capital per Share 3 Year Avg 0.4547
Working Capital per Share 5 Year Avg 1.1639 Beta 8.409813